Literature DB >> 3574140

Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.

A G Need, B E Chatterton, C J Walker, T A Steurer, M Horowitz, B E Nordin.   

Abstract

Most therapy for osteoporosis has been aimed at decreasing bone resorption and is capable of preventing further bone loss. Recently, anabolic steroids have been claimed to cause increased bone mass in osteoporosis, but the mechanism for this effect is not understood. In this study calcium, and calcium with calcitriol, caused a slowing of forearm bone mineral loss. Calcium and ovarian hormones, with or without calcitriol, caused a small non-significant rise in forearm mineral density, and nandrolone decanoate 50 mg intramuscularly, every 2 or 3 weeks caused a significant rise in forearm mineral density (+15.9 +/- 2.4 mg/ml/yr and +13.7 +/- 3.4 mg/ml/yr, respectively). The 3-weekly regime caused few side effects and is considered the optimal dose. The striking rise in bone density in patients in whom bone resorption was controlled before therapy, suggests that anabolic steroids can increase the bone formation rate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3574140     DOI: 10.1016/0378-5122(86)90035-6

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

Review 1.  Calcium supplementation of the diet: justified by present evidence.

Authors:  B E Nordin; R P Heaney
Journal:  BMJ       Date:  1990-04-21

Review 2.  Management of established osteoporosis.

Authors:  R M Francis
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

3.  [Prophylaxis and treatment of osteoporosis].

Authors:  H Kopera
Journal:  Klin Wochenschr       Date:  1989-05-15

Review 4.  Prevention and treatment of postmenopausal osteoporosis.

Authors:  R B Hallworth
Journal:  Pharm World Sci       Date:  1998-10

Review 5.  Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.

Authors:  P Geusens
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.